PCE (phencyclidine-ethyl, eticyclidine, or N-ethyl-1-phenylcyclohexylamine) is a synthetic dissociative anesthetic of the arylcyclohexylamine class, a close structural analog of phencyclidine (PCP) in which the piperidine ring is replaced by an N-ethyl group. PCE is one of the most potent dissociatives in the arylcyclohexylamine family, often described as more potent than PCP itself on a milligram basis, with a similarly intense and psychotomimetic character that demands serious respect and careful dose management.
PCE shares much of PCP's pharmacological profile — potent NMDA receptor antagonism, significant dopamine reuptake inhibition, sigma receptor activity — while the ethyl substitution modifies the pharmacokinetic profile and binding characteristics. Community and historical documentation describes PCE as producing a very intense, PCP-quality dissociation with pronounced stimulant properties and an elevated risk of psychosis and mania at high doses compared to ketamine-class compounds.
PCE occupies a significant historical position as one of the earliest PCP analogs to be systematically characterized, documented in pharmacological literature before the era of modern research chemicals. Its potency and PCP-like character have kept it at the margins of recreational use compared to more approachable ketamine analogs, but it is periodically available and has a dedicated community of experienced dissociative users who seek its particular pharmacological character.
Safety at a Glance
High Risk- Treat PCE as a High-Potency PCP Analog — Not a Ketamine Substitute
- A sober companion is essential for any dose above threshold
- Toxicity: Psychosis and Mania Risk As a potent PCP analog with significant dopaminergic activity, PCE's primary psychological t...
- Dangerous with: Acetylfentanyl, Buprenorphine, Codeine, Desomorphine (+15 more)
- Overdose risk: Overdose on PCE can range from unpleasant to life-threatening depending on the dose, route, and w...
If someone is in crisis, call 911 or Poison Control: 1-800-222-1222
Dosage
oral
smoked
insufflated
Duration
oral
Total: 4 hrs – 8 hrssmoked
Total: 4 hrs – 6 hrsinsufflated
Total: 4 hrs – 6 hrsHow It Feels
The onset is swift and arrives with unmistakable authority — a surging stimulation that gathers in the chest and radiates outward like a shockwave, reaching the extremities within ten to fifteen minutes. Your heart rate climbs, your pupils dilate, and a fierce mental energy ignites behind the eyes, as though someone has thrown open every window in a shuttered house simultaneously. There is nothing subtle about PCE. It arrives like a declaration, and from the first moment it makes clear that it intends to run the show.
The come-up is dominated by the stimulant component, which is more aggressive and forward than most dissociatives in this family. Your thoughts accelerate dramatically — not into chaos but into a kind of pressurized clarity, each idea arriving with tremendous force and apparent significance. Speech becomes rapid and fluent; you feel capable of articulating concepts that normally elude language. The body is powerfully numb but does not feel heavy or sedated — instead, it hums with energy, restless and kinetic, wanting to move, to pace, to gesture. The dissociation builds underneath this stimulation like a second story being constructed beneath a first: you become aware that the ground is further away than it should be, that your relationship to your own body has become one of remote operation rather than direct inhabitation.
At the peak, the mania and the dissociation merge into a state of extraordinary intensity. You feel, simultaneously, deeply detached from reality and absolutely certain about everything within it. The world has become a puzzle you have just solved; every object, every sound, every face is a symbol in a system you can finally read. Music is overwhelming — not beautiful so much as significant, as though it is transmitting information of critical importance. The body is a distant instrument, powerful and numb, capable of feats that seem effortless. At higher doses, the certainty can spiral into frank delusion, and the line between insight and psychosis becomes invisible to the person standing on it.
The descent is long and difficult. The stimulation persists for many hours, refusing to yield to exhaustion. The grandiosity fades first, leaving behind a driven wakefulness that has lost its object — you are still accelerated but no longer know why. Sleep may be impossible for eight or ten hours after the peak. The aftermath is depleting: flat mood, physical fatigue, a sense that the engine has been running in the red for too long. Recovery takes time. PCE demands a full day, sometimes two, before baseline is truly restored.
Subjective Effects
The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.
Physical Effects
Physical(5)
- Pain relief— A suppression of negative physical sensations such as aches and pains, ranging from dulled awareness...
- Physical fatigue— Physical fatigue is a state of bodily exhaustion characterized by reduced energy, diminished capacit...
- Respiratory depression— A dangerous slowing and shallowing of breathing that can progress from barely noticeable reductions ...
- Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
- Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Cognitive & Perceptual Effects
Cognitive(9)
- Amnesia— A complete or partial inability to form new memories or recall existing ones during and after substa...
- Confusion— An impairment of abstract thinking marked by a persistent inability to grasp or comprehend concepts ...
- Delirium— Delirium is a serious and potentially dangerous state of acute mental confusion involving disorienta...
- Delusion— A delusion is a fixed, false belief that is held with unshakeable certainty and is impervious to con...
- Depression— A persistent state of low mood, emotional numbness, hopelessness, and diminished interest or pleasur...
- Mania— Abnormally elevated mood, energy, and activity with impulsive behavior and grandiosity, associated w...
- Paranoia— Irrational suspicion and belief that others are watching, plotting against, or intending harm toward...
- Psychosis— Psychosis is a serious psychiatric state involving a fundamental break from consensus reality — char...
- Wakefulness— An increased ability to stay awake and alert without the desire to sleep. Distinct from stimulation ...
Pharmacology
Mechanism of Action
PCE acts as a potent non-competitive NMDA receptor antagonist, blocking the NMDA ion channel through the same open-channel trapping mechanism as PCP and ketamine. Its binding affinity at the NMDA receptor is high — in the same range as PCP and significantly higher than ketamine — consistent with its potency in human experience.
Dopaminergic Activity
Like PCP, PCE has significant dopamine reuptake inhibitory activity. This dopaminergic component:
- Produces stimulant effects (elevated energy, arousal, reduced sedation compared to ketamine)
- Contributes to euphoria and elevated abuse potential
- Is the primary mechanism underlying the psychosis and mania risk at high doses
- Creates a qualitatively different "stimulant-dissociative" experience compared to ketamine-like compounds
Sigma Receptor Activity
Sigma receptor agonism (shared with PCP and other arylcyclohexylamines) contributes to additional perceptual distortions and may modulate mood and stimulant effects.
Potency
PCE is more potent than PCP by weight in some estimates, and substantially more potent than ketamine. Active doses begin in the single-digit milligrams range. This high potency demands precise dose control.
Duration
PCE has a longer duration than ketamine — typically 4–6 hours — reflecting different pharmacokinetic processing of the N-ethyl group versus ketamine's methylamine.
Detection Methods
Standard Drug Panel Inclusion
PCE (eticyclidine, N-ethyl-PCP) may trigger a positive result on standard PCP immunoassay screens due to its close structural similarity to PCP. The only structural difference is the ethyl group on nitrogen instead of the cyclohexyl group. Cross-reactivity with PCP immunoassays varies by platform, with some producing positive results and others returning negative or borderline results.
Urine Detection
PCE is detectable in urine for approximately 3 to 7 days after a single dose. The compound is metabolized by hepatic oxidation, producing hydroxylated metabolites. A portion is excreted unchanged in urine. The arylcyclohexylamine structure promotes lipophilic accumulation and extended detection windows comparable to PCP. Reliable detection requires LC-MS/MS methods specifically targeting PCE.
Blood and Serum Detection
Blood detection windows are approximately 1 to 3 days. PCE is a Schedule I substance with very limited legitimate use, and pharmacokinetic data comes primarily from forensic case reports and older pharmacological studies. Active blood concentrations are in the nanogram-per-milliliter range.
Hair Follicle Detection
Hair analysis for PCE is feasible using LC-MS/MS methods, with expected detection windows of up to 90 days. The basic, lipophilic nature of the compound favors hair incorporation.
Confirmatory Methods
GC-MS and LC-MS/MS can both confirm PCE exposure. The compound produces characteristic mass spectral fragmentation patterns that are related to but distinguishable from PCP. Reference standards are available from forensic chemistry suppliers.
Reagent Testing
PCE shows similar reagent profiles to PCP. The Mandelin reagent may produce an orange-brown color. The Simon reagent detects secondary amines and may produce a blue response. Reagent testing cannot definitively distinguish PCE from PCP or other arylcyclohexylamine analogues.
Interactions
| Substance | Status | Note |
|---|---|---|
| Acetylfentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Buprenorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Codeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Desomorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dextropropoxyphene | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Dihydrocodeine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Ethylmorphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Fentanyl | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Heroin | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydrocodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Hydromorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Kratom | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Methadone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Morphine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Naloxone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| O-Desmethyltramadol | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxycodone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Oxymorphone | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| Pethidine | Dangerous | Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration |
| 1,4-Butanediol | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 2-Fluorodeschloroketamine | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 2M2B | Caution | Both cause CNS depression; increased risk of vomiting, unconsciousness, and respiratory depression |
| 3-Cl-PCP | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 3-HO-PCE | Caution | Compounding dissociative effects can cause confusion, mania, and loss of motor control |
| 1,3-Butanediol | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1B-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-AL-LAD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-LSD | Low Risk & Synergy | Produces unique synergistic effects; often combined |
| 1cP-MiPLA | Low Risk & Synergy | Produces unique synergistic effects; often combined |
History
Early Development and Research
PCE was among the first PCP analogs synthesized in the systematic SAR research of the 1950s–1970s exploring the pharmacology of arylcyclohexylamines. Researchers at Parke-Davis and other institutions explored N-substituted analogs of PCP seeking compounds with improved therapeutic indices — specifically, useful anesthetic or analgesic activity without PCP's psychotomimetic side effects. PCE was characterized in this context and found to share PCP's psychotomimetic properties.
Historical Literature
PCE appears in the pharmacological literature of the 1970s and 1980s as part of the broader study of PCP analogs. Its potency and PCP-like character were established through animal studies and limited human pharmacology.
Research Chemical Era
PCE periodically appeared in the research chemical market alongside other PCP analogs. Its high potency and overtly PCP-like character limited broad adoption compared to more approachable ketamine analogs, but it maintained interest among experienced dissociative users specifically seeking the PCP-class experience character.
Legal Status
As a direct PCP analog, PCE is covered by analogue legislation in the United States and many other jurisdictions. PCP is Schedule II in the US; PCE would be treated as an analogue under federal law. Various countries have explicitly scheduled PCP analogs, and PCE's legal status follows the trajectory of the broader arylcyclohexylamine scheduling history.
Harm Reduction
Treat PCE as a High-Potency PCP Analog — Not a Ketamine Substitute
PCE's pharmacological character is closer to PCP than to ketamine. The appropriate harm reduction framework is that of a potent stimulant-dissociative with high psychosis risk, not a sedating dissociative like ketamine:
- A sober companion is essential for any dose above threshold
- Physical and social environment must be carefully controlled
- Do not use in any situation where behavioral impairment could cause harm to yourself or others
Extremely Low Starting Doses
Given high potency:
- Start with 1–3 mg for a test dose
- Volumetric dosing from a stock solution is recommended given the milligram-range doses
- Wait the full expected duration (4–6 hours) before any assessment
Psychosis Risk Assessment
Screen yourself honestly for psychosis risk factors:
- Personal history of psychosis, mania, or schizophrenia
- Family history of psychotic disorders
- Current psychological vulnerability or instability
These represent strong contraindications for PCE.
Avoid All Stimulant Combinations
The dopaminergic activity makes stimulant combinations (amphetamines, cocaine, MDMA) extremely high-risk from both cardiovascular and psychosis-induction perspectives.
Bladder and Urological Monitoring
As with all arylcyclohexylamines, limit use frequency and monitor for urological symptoms with regular use.
Toxicity & Safety
Psychosis and Mania Risk
As a potent PCP analog with significant dopaminergic activity, PCE's primary psychological toxicity risk is psychosis — paranoia, delusions, hallucinations, and disorganized thinking — particularly at high doses. The risk is substantially higher than for ketamine-class compounds and comparable to PCP itself. Individuals with personal or family history of psychotic disorders should treat PCE as absolutely contraindicated.
High-Dose Behavioral Toxicity
At high doses, PCE produces behavioral patterns analogous to acute PCP intoxication: agitation, combativeness, extreme confusion, loss of self-control. The combination of stimulant and dissociative effects can produce unpredictable and dangerous behavior that may require emergency intervention.
Cardiovascular Effects
The dopaminergic component produces meaningful cardiovascular stimulation — elevated heart rate, blood pressure, and body temperature. At high doses or in combination with stimulants, this can reach clinically significant levels.
Respiratory Depression
At very high doses combined with CNS depressants, respiratory depression is possible. The stimulant character may partially mask sedation warning signs, making overdose recognition more difficult.
Abuse Potential and Dependence
The dopamine reuptake inhibition gives PCE high abuse potential comparable to PCP. Psychological dependence and compulsive use patterns are meaningful risks.
Addiction Potential
highly addictive with a high potential for adverse side effects such as psychosis
Overdose Information
Overdose on PCE can range from unpleasant to life-threatening depending on the dose, route, and whether other substances are involved.
Signs of overdose: Severe nystagmus, complete unresponsiveness, vomiting (aspiration risk while unconscious), severely depressed breathing, seizures, extremely elevated heart rate or blood pressure.
Critical dangers:
- Respiratory depression: Particularly when combined with other depressants
- Aspiration: Loss of protective reflexes combined with nausea creates choking risk
- Hyperthermia or hypothermia: Impaired thermoregulation at high doses
Emergency response: Place the person in the recovery position. Monitor breathing. Call emergency services if breathing is slow, shallow, or irregular; if the person is unresponsive to stimulation; or if seizures occur. Be honest with medical personnel about what was consumed — they are there to help, not to judge.
Dangerous Interactions
The combinations listed below may be life-threatening. Independent research should always be conducted to ensure safety when combining substances.
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Both cause respiratory depression and unconsciousness; vomiting while dissociated risks aspiration
Tolerance
| Full | with prolonged and repeated use |
| Half | 3 - 7 days |
| Zero | 1 - 2 weeks |
Cross-tolerances
Legal Status
Internationally, PCE is a Schedule I substance under the Convention on Psychotropic Substances.
Canada** - PCE is controlled under CDSA schedule III making it illegal to sell, possess and manufacture without a license or prescription.
Germany:** PCE is controlled under BtMG Anlage I, making it illegal to manufacture, import, possess, sell, or transfer it without a license.
New Zealand** - PCE is Schedule I (class A) in New Zealand.
Poland** - PCE is Schedule II (II-P group) in Poland.
Portugal** - Effective July 2001, personal use of PCE was decriminalized by Law 30/2000. Possession of less than 100 mg is not regarded as a criminal offence, although the substance is liable to be seized and the possessor can be referred to mandatory treatment. Sale or possession of quantities greater than the personal possession limit are criminal offences punishable by jail time.
Switzerland:** PCE is a controlled substance specifically named under Verzeichnis D.
United Kingdom** - PCE is a class A in the U.K., making it illegal to buy or possess without a prescription.
United States **- PCE is a Schedule II controlled substance.
Responsible use
Volumetric liquid dosing
Research chemical
Dissociative
PCE (Wikipedia)
PCE (Isomer Design)
Morris, H., & Wallach, J. (2014). From PCP to MXE: A comprehensive review of the non-medical use of dissociative drugs. Drug Testing and Analysis, 6(7–8), 614–632. https://doi.org/10.1002/dta.1620
Tips (5)
Weigh your dose of PCE with a milligram scale. Dissociative dose-response curves are steep. The difference between a pleasant floaty experience and complete dissociation from reality can be 50mg or less.
Do not combine PCE with other CNS depressants (alcohol, opioids, benzodiazepines). Dissociatives already depress breathing and cardiovascular function. Adding other depressants creates dangerous respiratory depression.
Test PCE with appropriate reagent kits. Dissociative powders are frequently mislabeled or adulterated. A Mandelin reagent test helps distinguish between some common dissociatives. Always use fentanyl test strips as well.
Choose a safe physical environment before using PCE. Remove sharp objects, secure stairs, and create a comfortable space to lie or sit. Dissociation makes spatial awareness unreliable and falls are common.
Never use PCE near water (bathtubs, pools, lakes). Dissociation and water are a deadly combination. Loss of body coordination and awareness while near water has caused drownings.
See Also
References (4)
- Ketamine as a rapid antidepressant — Berman et al. Biological Psychiatry (2000)paper
- PubChem: PCE
PubChem compound page for PCE (CID: 31373)
pubchem - PCE - TripSit Factsheet
TripSit factsheet for PCE
tripsit - PCE - Wikipedia
Wikipedia article on PCE
wikipedia